256 related articles for article (PubMed ID: 31141239)
1. B.A.R.C.O.S. (Brazilian Argentine Hepatitis C Collaborative Observational Study): Effectiveness and clinical outcomes of HCV treatment with daclatasvir and sofosbuvir with or without ribavirin.
Ridruejo E; Cheinquer H; Marciano S; Mendizabal M; Piñero F; Wolff FH; de Araujo A; Coelho Borges S; Kliemann D; Fleck A; de Maman Í; Nader LA; Garrastazul P; Bermúdez C; Haddad L; Gadano A; Silva M
J Viral Hepat; 2019 Oct; 26(10):1200-1209. PubMed ID: 31141239
[TBL] [Abstract][Full Text] [Related]
2. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
3. High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study.
Darweesh SK; Elsaeed K; Omar H; El Raziky M; Elakel W; Elserafy M; Ismail SA; Gomaa AA; Mehrez M; El Kassas M; Abdullah M; Shaker MK; Esmat G; El Shazly Y; Doss W; Waked I
Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):907-914. PubMed ID: 31173527
[No Abstract] [Full Text] [Related]
4. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience.
Shiha G; Soliman R; ElBasiony M; Hassan AA; Mikhail NNH
Hepatol Int; 2018 Jul; 12(4):339-347. PubMed ID: 29663115
[TBL] [Abstract][Full Text] [Related]
5. Sofosbuvir plus daclatasvir with or without ribavirin is safe and effective for post-transplant hepatitis C recurrence and severe fibrosis and cirrhosis: A prospective study.
Lionetti R; Calvaruso V; Piccolo P; Mancusi RL; Mazzarelli C; Fagiuoli S; Montalbano M; Lenci I; Carrai P; Guaraldi G; Visco-Comandini U; Milana M; Biolato M; Loiacono L; Valente G; Craxì A; Angelico M; D'offizi G
Clin Transplant; 2018 Feb; 32(2):. PubMed ID: 29193356
[TBL] [Abstract][Full Text] [Related]
6. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
[TBL] [Abstract][Full Text] [Related]
7. Real-world safety and effectiveness of retreatment of Egyptian chronic hepatitis C patients not responding to NS5A inhibitor-based therapies.
Yousif MM; Ahmed H; Elsadek HM; Shendi AM; Gouda TM; Elsayed IA; Gendia MA; Magdy MM; Lbrahim NF; Sadek AMEM; Zaki AM; Shafeik H; Zahran MH
J Viral Hepat; 2020 Nov; 27(11):1190-1201. PubMed ID: 32564500
[TBL] [Abstract][Full Text] [Related]
8. High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar.
Hlaing NKT; Nangia G; Tun KT; Lin S; Maung MZ; Myint KT; Kyaw AMM; Maung ST; Sein Win S; Bwa AH; Loza BL; Win KM; Reddy KR
J Viral Hepat; 2019 Oct; 26(10):1186-1199. PubMed ID: 31104344
[TBL] [Abstract][Full Text] [Related]
9. Satisfactory virological response and fibrosis improvement of sofosbuvir-based regimens for Chinese patients with hepatitis C virus genotype 3 infection: results of a real-world cohort study.
Tao YC; Deng R; Wang ML; Lv DD; Yuan M; Wang YH; Chen EQ; Tang H
Virol J; 2018 Oct; 15(1):150. PubMed ID: 30285800
[TBL] [Abstract][Full Text] [Related]
10. High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients.
Pellicelli A; Messina V; Giannelli V; Distefano M; Palitti VP; Vignally P; Tarquini P; Izzi A; Moretti A; Babudieri S; Dell'Isola S; Marignani M; Scifo G; Iovinella V; Cariti G; Pompili M; Candilo FD; Fontanella L; Ettorre GM; Vennarecci G; Ippolito AM; Barbarini G
Gut Liver; 2020 May; 14(3):357-367. PubMed ID: 30970444
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
Alonso S; Riveiro-Barciela M; Fernandez I; Rincón D; Real Y; Llerena S; Gea F; Olveira A; Fernandez-Carrillo C; Polo B; Carrión JA; Gómez A; Devesa MJ; Baliellas C; Castro Á; Ampuero J; Granados R; Pascasio JM; Rubín A; Salmeron J; Badia E; Planas JM; Lens S; Turnes J; Montero JL; Buti M; Esteban R; Fernández-Rodríguez CM
J Viral Hepat; 2017 Apr; 24(4):304-311. PubMed ID: 27935168
[TBL] [Abstract][Full Text] [Related]
12. Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil.
Lobato CMO; Codes L; Silva GF; Souza AFM; Coelho HSM; Pedroso MLA; Parise ER; Lima LMSTB; Borba LA; Evangelista AS; Rezende REF; Cheinquer H; Kuniyoshi ASO; Aires RS; Quintela EHD; Mendes LSC; Nascimento FCV; Medeiros Filho JEM; Ferraz MLCG; Abdala E; Bittencourt PL; ;
Ann Hepatol; 2019; 18(6):849-854. PubMed ID: 31537509
[TBL] [Abstract][Full Text] [Related]
13. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacy of sofosbuvir-ribavirin versus sofosbuvir-daclatasvir for treatment of chronic hepatitis C in an area with limited NS5A inhibitor availability.
Kurniawan J; Gani RA; Hasan I; Sulaiman AS; Lesmana CRA; Jasirwan COM; Kalista KF; Nababan SHH; Zulkifly S
Indian J Gastroenterol; 2018 Nov; 37(6):520-525. PubMed ID: 30637537
[TBL] [Abstract][Full Text] [Related]
15. Effect of adding daclatasvir in sofosbuvir-based therapy in genotype 3 hepatitis C: real-world experience in Pakistan.
Sarwar S; Tarique S; Aleem A; Khan AA
Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1035-1039. PubMed ID: 31274596
[TBL] [Abstract][Full Text] [Related]
16. Real-world effectiveness and safety of sofosbuvir plus daclatasvir with or without ribavirin for genotype 2 chronic hepatitis C in Taiwan.
Cheng PN; Chiu YC; Chien SC; Chiu HC
J Formos Med Assoc; 2019 May; 118(5):907-913. PubMed ID: 30316677
[TBL] [Abstract][Full Text] [Related]
17. Sofosbuvir based treatment of chronic hepatitis C genotype 3 infections-A Scandinavian real-life study.
Dalgard O; Weiland O; Noraberg G; Karlsen L; Heggelund L; Färkkilâ M; Balslev U; Belard E; Øvrehus A; Skalshøi Kjær M; Krarup H; Thorup Røge B; Hallager S; Madsen LG; Lund Laursen A; Lagging M; Weis N
PLoS One; 2017; 12(7):e0179764. PubMed ID: 28704381
[TBL] [Abstract][Full Text] [Related]
18. Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection.
Liu CH; Su TH; Liu CJ; Hong CM; Yang HC; Tseng TC; Chen PJ; Chen DS; Kao JH
J Gastroenterol Hepatol; 2019 Sep; 34(9):1620-1625. PubMed ID: 30693965
[TBL] [Abstract][Full Text] [Related]
19. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.
Fontana RJ; Brown RS; Moreno-Zamora A; Prieto M; Joshi S; Londoño MC; Herzer K; Chacko KR; Stauber RE; Knop V; Jafri SM; Castells L; Ferenci P; Torti C; Durand CM; Loiacono L; Lionetti R; Bahirwani R; Weiland O; Mubarak A; ElSharkawy AM; Stadler B; Montalbano M; Berg C; Pellicelli AM; Stenmark S; Vekeman F; Ionescu-Ittu R; Emond B; Reddy KR
Liver Transpl; 2016 Apr; 22(4):446-58. PubMed ID: 26890629
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of sofosbuvir-based therapy in hepatitis C virus recurrence post living donor liver transplant: A real life egyptian experience.
Yosry A; Gamal Eldeen H; Medhat E; Mehrez M; Zayed N; Elakel W; Abdelmoniem R; Kaddah M; Abdelaziz A; Esmat G; El-Serafy M; Doss W
J Med Virol; 2019 Apr; 91(4):668-676. PubMed ID: 30549048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
